Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5231036 | 0.88 | L3MBTL1 (0.43) | ALDH1A1MAPTKDM4ETDP1L3MBTL1 | |
| SCHEMBL5233865 | 0.86 | KDM4E (0.41) | ALDH1A1MAPTKDM4EKMT2AMEN1 | |
| SCHEMBL5237691 | 0.82 | ALDH1A1 (0.44) | ALDH1A1MAPTKDM4EDPP4TSHR | |
| SCHEMBL5234822 | 0.82 | ALDH1A1 (0.40) | ALDH1A1MAPTMAPK8KDM4EKMT2A | |
| SCHEMBL5234819 | 0.81 | ALDH1A1 (0.39) | ALDH1A1MAPTKDM4EKMT2ADPP4 | |
| SCHEMBL5236956 | 0.80 | DPP4 (0.47) | ALDH1A1KDM4EDPP4TSHRSMN1; SMN2 | |
| SCHEMBL5238223 | 0.80 | ALDH1A1 (0.44) | ALDH1A1KDM4EDPP4TSHRSMN1; SMN2 | |
| SCHEMBL6106133 | 0.79 | ALDH1A1 (0.38) | ALDH1A1MAPTMAPK8KDM4EKMT2A | |
| SCHEMBL6106130 | 0.79 | ALDH1A1 (0.37) | ALDH1A1MAPTMAPK8KDM4EKMT2A | |
| SCHEMBL5233440 | 0.77 | L3MBTL1 (0.39) | ALDH1A1MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355886-B1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2007-07-11 | — | — | EP | disclosed |
| US-7034039-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-04-25 | — | — | US | disclosed |
| US-20040082607-A1 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082607-A1 | Fused heterocyclic compounds | DPP7, DPP4, METAP1 | ALDH1A1 387/4885MAPT 4855/4885MAPK8 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.